[Intra-erythrocytic GOT activity in uremia and its behavior following pyridoxine administration].
A significant decrease of the glutamic oxalacetic transaminase activity of erythrocytes (EGOT) was found in patients on regular dialysis treatment. When pyridoxal-5-phosphate, the active metabolite of vitamin B6, was added to the samples, EGOT activity increased in dialysis patients and in normals, but the activity obtained after stimulation was not as high in haemodialyzed patients as in volunteers. In normals and in patients under pyridoxine treatment the EGOT activity was significantly higher when compared to the corresponding groups without vitamin B6 administration, the EGOT activity depending on duration of pyridoxine treatment.
D001219:Aspartate Aminotransferases / Q000378:metabolism*; D003131:Combined Modality Therapy; D004912:Erythrocytes / Q000201:enzymology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000201:enzymology*; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D011736:Pyridoxine / Q000494:pharmacology* / Q000627:therapeutic use; D006435:Renal Dialysis; D014511:Uremia / Q000188:drug therapy / Q000201:enzymology*
D011732:Pyridoxal Phosphate; D001219:Aspartate Aminotransferases; D011736:Pyridoxine
Die intraerythrozytäre GOT-Aktivität bei Urämie und ihr Verhalten unter Pyridoxinapplikation.